$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023019233 Filed on March 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$13.00M	$19.65M	$62.45M
YoY Change	-5.31%	-3.24%	1.89%
Cost Of Revenue	$5.570M	$7.200M	$23.48M
YoY Change	-1.07%	-9.1%	-8.46%
Gross Profit	$7.433M	$12.45M	$38.97M
YoY Change	-8.25%	0.51%	9.34%
Gross Profit Margin	57.17%	63.37%	62.4%
Selling, General & Admin	$14.03M	$26.67M	$33.49M
YoY Change	23.19%	146.05%	0.9%
% of Gross Profit	188.78%	214.17%	85.94%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$463.9K	$456.6K	$2.022M
YoY Change	-1.61%	18.54%	2.88%
% of Gross Profit	6.24%	3.67%	5.19%
Operating Expenses	$14.50M	$13.32M	$51.26M
YoY Change	22.2%	13.15%	45.3%
Operating Profit	-$7.063M	-$864.3K	-$12.29M
YoY Change	87.8%	-239.17%	-3503.69%
Interest Expense	$665.5K	$538.5K	$852.3K
YoY Change		22526.47%	4919.43%
% of Operating Profit
Other Income/Expense, Net	$665.5K		$852.3K
YoY Change	22182300.0%
Pretax Income	-$6.398M	-$325.8K	-$11.44M
YoY Change	70.1%	-152.26%	-3125.4%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$6.398M	-$325.8K	-$11.44M
YoY Change	70.1%	-152.26%	-3125.4%
Net Earnings / Revenue	-49.2%	-1.66%	-18.32%
Basic Earnings Per Share	-$0.37		-$0.64
Diluted Earnings Per Share	-$0.37	-$0.02	-$0.64
COMMON SHARES
Basic Shares Outstanding	17.10M shares	17.15M shares	17.78M shares
Diluted Shares Outstanding	17.09M shares		17.78M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$73.70M	$74.14M	$74.14M
YoY Change	-17.15%	-12.45%	-12.45%
Cash & Equivalents	$16.44M	$18.21M	$18.21M
Short-Term Investments	$57.26M	$55.93M	$55.93M
Other Short-Term Assets	$4.015M	$2.281M	$2.281M
YoY Change	-12.9%	-59.49%	-59.49%
Inventory
Prepaid Expenses		$2.281M
Receivables	$18.16M	$22.16M	$22.16M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$95.88M	$98.58M	$98.58M
YoY Change	-14.92%	-14.37%	-14.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$143.9K	$137.4K	$372.8K
YoY Change	4.72%	-70.92%	-21.13%
Goodwill	$22.67M	$22.67M
YoY Change		53.82%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$5.050K	$5.050K
YoY Change		-60.73%	-60.73%
Total Long-Term Assets	$35.81M	$36.07M	$36.07M
YoY Change	40.77%	39.43%	39.43%
TOTAL ASSETS
Total Short-Term Assets	$95.88M	$98.58M	$98.58M
Total Long-Term Assets	$35.81M	$36.07M	$36.07M
Total Assets	$131.7M	$134.7M	$134.7M
YoY Change	-4.67%	-4.49%	-4.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.289M	$1.550M	$1.550M
YoY Change	114.55%	155.43%	155.43%
Accrued Expenses	$2.125M	$2.601M	$2.691M
YoY Change	17.67%	-13.11%	-10.11%
Deferred Revenue	$735.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.606M	$8.396M	$8.396M
YoY Change	10.62%	-10.38%	-10.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$123.2K	$144.5K	$144.5K
YoY Change	-42.13%	-38.95%	-38.95%
Total Long-Term Liabilities	$123.2K		$144.5K
YoY Change	-42.13%		-38.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.606M	$8.396M	$8.396M
Total Long-Term Liabilities	$123.2K		$144.5K
Total Liabilities	$7.729M	$8.540M	$8.540M
YoY Change	9.04%	-11.09%	-11.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.09M	-$46.69M
YoY Change		32.45%
Common Stock	$18.33K	$18.29K
YoY Change		2.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.214K	$1.214K
YoY Change
Treasury Stock Shares		1.214M shares
Shareholders Equity	$124.0M	$126.1M	$126.1M
YoY Change
Total Liabilities & Shareholders Equity	$131.7M	$134.7M	$134.7M
YoY Change	-4.67%	-4.49%	-4.49%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.398M	-$325.8K	-$11.44M
YoY Change	70.1%	-152.26%	-3125.4%
Depreciation, Depletion And Amortization	$463.9K	$456.6K	$2.022M
YoY Change	-1.61%	18.54%	2.88%
Cash From Operating Activities	-$86.33K	$2.803M	$10.65M
YoY Change	-102.12%	-310.07%	1367.42%
INVESTING ACTIVITIES
Capital Expenditures	$28.58K	$178.1K	$81.01K
YoY Change	-297.38%	-144.3%	-117.44%
Acquisitions			$2.000M
YoY Change
Other Investing Activities	-$1.326M	-$18.31M	-$57.93M
YoY Change	2487.11%	-6143.72%	269233.57%
Cash From Investing Activities	-$1.549M	-$18.48M	-$58.18M
YoY Change	2255.73%	18567.45%	11870.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$20.02M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$129.8K	-7.439M	-$18.95M
YoY Change	-150.28%	-802.65%	-125.64%
NET CHANGE
Cash From Operating Activities	-$86.33K	2.803M	$10.65M
Cash From Investing Activities	-$1.549M	-18.48M	-$58.18M
Cash From Financing Activities	-$129.8K	-7.439M	-$18.95M
Net Change In Cash	-$1.765M	-23.12M	-$66.47M
YoY Change	-141.31%	6068.55%	-189.63%
FREE CASH FLOW
Cash From Operating Activities	-$86.33K	$2.803M	$10.65M
Capital Expenditures	$28.58K	$178.1K	$81.01K
Free Cash Flow	-$114.9K	$2.625M	$10.57M
YoY Change	-102.81%	-381.51%	788.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38543
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1265381
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Water Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rochester
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48307
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2022	dei	Trading Symbol TradingSymbol	OPRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	486888119	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17100097	shares
CY2022	dei	Auditor Name AuditorName	UHY LLP
CY2022	dei	Auditor Location AuditorLocation	Sterling Heights, Michigan
CY2022	dei	Auditor Firm AuditorFirmId	1195
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18208685	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84681770	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	55931821	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22155301	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24800585	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2280828	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5630655	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98576635	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	115113010	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143818	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14740031	usd
CY2022Q4	oprx	Technology Assets Net TechnologyAssetsNet	7702895	usd
CY2021Q4	oprx	Technology Assets Net TechnologyAssetsNet	4589126	usd
CY2022Q4	us-gaap	Mineral Properties Net MineralPropertiesNet	1940178	usd
CY2021Q4	us-gaap	Mineral Properties Net MineralPropertiesNet	2155026	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235320	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	328820	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3379838	usd
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3902502	usd
CY2022Q4	oprx	Other Assets And Deposits OtherAssetsAndDeposits	5051	usd
CY2021Q4	oprx	Other Assets And Deposits OtherAssetsAndDeposits	12859	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	35937102	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	25728364	usd
CY2022Q4	us-gaap	Assets Assets	134651185	usd
CY2021Q4	us-gaap	Assets Assets	140985192	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1549979	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	606808	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2601246	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2902836	usd
CY2022Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3990440	usd
CY2021Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	4378216	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89902	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	90982	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1389907	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8395876	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9368749	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144532	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	236726	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8540408	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9605475	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18288571	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18288571	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17860975	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17860975	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18289	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17861	usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1214398	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1214398	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172785800	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	166615514	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46692098	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35253658	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134651185	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140985192	usd
CY2022	us-gaap	Revenues Revenues	62450156	usd
CY2021	us-gaap	Revenues Revenues	61292598	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	23483336	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	25654384	usd
CY2022	us-gaap	Gross Profit GrossProfit	38966820	usd
CY2021	us-gaap	Gross Profit GrossProfit	35638214	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	15745822	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5491957	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2022029	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2086454	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33489707	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27698703	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	51257558	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	35277114	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12290738	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	361100	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	852298	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16979	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11438440	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	378079	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	378079	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17783992	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17228019	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17783992	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17690489	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022	oprx	Stockbased Compensation Expense Options StockbasedCompensationExpenseOptions	4956619	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	10789203	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1205881	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9374455	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-132400	usd
CY2022	oprx	Repurchase Of Common Stock RepurchaseOfCommonStock	20021830	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	49973914	usd
CY2021	oprx	Stockbased Compensation Expense Options StockbasedCompensationExpenseOptions	2709781	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2532088	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250085	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4864231	usd
CY2021	oprx	Public Offering Of Common Shares Net Of Offering Costs PublicOfferingOfCommonSharesNetOfOfferingCosts	70671536	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	378079	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-11438440	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	378079	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2022029	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1965325	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	363512	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	80000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15745822	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5491957	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2281773	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6994880	usd
CY2022	oprx	Lease Liabilities Arising From Right Of Use Assets LeaseLiabilitiesArisingFromRightOfUseAssets	2650951	usd
CY2021	oprx	Lease Liabilities Arising From Right Of Use Assets LeaseLiabilitiesArisingFromRightOfUseAssets	-1174044	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	943171	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11442	usd
CY2022	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-387776	usd
CY2021	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-591652	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-301592	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	482475	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	226	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3891	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1225598	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1104112	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10654078	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	726039	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	81005	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100322	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2000000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	55931821	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1830	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21511	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	161730	usd
CY2021	us-gaap	Payments For Software PaymentsForSoftware	364166	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58176386	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-485999	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70671536	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	20024258	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1073481	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4864231	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1610813	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18950777	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73924954	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66473085	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74164994	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10516776	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2022	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid	708334	usd
CY2022	oprx	Shares Issued In Connection With Acquisitions SharesIssuedInConnectionWithAcquisitions	9374455	usd
CY2022	oprx	Us Healthcare Providers Percentage USHealthcareProvidersPercentage	0.60	pure
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2110865	usd
CY2020Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	757218	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11438440	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain items in the previous year financial statements have been reclassified to match the current year presentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	363512	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	80000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	352043	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	241219	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3582735	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	55437418	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	57077743	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7012738	usd
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4214855	usd
CY2022	us-gaap	Revenues Revenues	62450156	usd
CY2021	us-gaap	Revenues Revenues	61292598	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.50	pure
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11438440	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17783992	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risks</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2022 and 2021 the Company had $15,669,837 and $83,312,524, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	15669837	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	83312524	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2022	oprx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Turnoverforfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTurnoverforfeitureRate	0	pure
CY2021	oprx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Turnoverforfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTurnoverforfeitureRate	0	pure
CY2022	oprx	Weighted Average Grant Date Fair Valuein Dollars Per Share WeightedAverageGrantDateFairValueinDollarsPerShare	12.82	usd
CY2021	oprx	Weighted Average Grant Date Fair Valuein Dollars Per Share WeightedAverageGrantDateFairValueinDollarsPerShare	26.36	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	93626	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	170859	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17783992	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	378079	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17228019	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2021	oprx	Effect Of Dilutive Securities Shares EffectOfDilutiveSecuritiesShares	462470	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	378079	usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17690489	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	2280828	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	5630655	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1769212	usd
CY2022Q2	oprx	Issuance Of Shares Of Common Stock IssuanceOfSharesOfCommonStock	240741	shares
CY2022Q2	oprx	Business Acquisition Common Stock Value BusinessAcquisitionCommonStockValue	9374455	usd
CY2022Q2	oprx	Purchase Price PurchasePrice	12082789	usd
CY2022Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	185185	shares
CY2022Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2022Q2	us-gaap	Goodwill Gross GoodwillGross	7933789	usd
CY2022Q2	us-gaap	Acquisition Costs AcquisitionCosts	19739	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	55900000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1025000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4516668	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	408063	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	181044	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	221580	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	156327	usd
CY2022Q4	oprx	Property Plantand Equipment Data PropertyPlantandEquipmentData	152533	usd
CY2021Q4	oprx	Property Plantand Equipment Data PropertyPlantandEquipmentData	168462	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	473652	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	608154	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268967	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	468167	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	131519	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	324349	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143818	usd
CY2022	us-gaap	Depreciation Depreciation	85725	usd
CY2021	us-gaap	Depreciation Depreciation	105360	usd
CY2020Q4	us-gaap	Goodwill Goodwill	14740031	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14740031	usd
CY2022	us-gaap	Deferred Revenue Refund Payments1 DeferredRevenueRefundPayments1	7933789	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	21826389	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8803478	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13022911	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	17513828	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6867174	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	10646654	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	1936304	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	1859965	usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1769212	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1682054	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1566184	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1483765	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	4752484	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13022911	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1389907	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1389907	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-36346653	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	35121055	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	285795	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-18006973	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	19111085	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1389907	usd
CY2010Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	930000	usd
CY2022	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	401972	usd
CY2021	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	218333	usd
CY2021Q4	oprx	Share Based Compensation Arrangement By Share Based Payment Award Options Withheld And Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithheldAndCancelledInPeriod	31243	shares
CY2021	oprx	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Withheldand Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageWithheldandCancelled	3.21
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	49494	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	24.57
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	156910	shares
CY2022	oprx	Gross Proceeds Of Common Stock Amount GrossProceedsOfCommonStockAmount	1205881	usd
CY2021	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1105822	shares
CY2021	oprx	Gross Proceeds Of Common Stock Amount GrossProceedsOfCommonStockAmount	4864231	usd
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1523750	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75425625	usd
CY2021	oprx	Issuance Of Common Stock Exercise Value IssuanceOfCommonStockExerciseValue	4754089	usd
CY2021	oprx	Payments To Advisors And Legal Fees PaymentsToAdvisorsAndLegalFees	70671536	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1214398	shares
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	20024258	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3000000	shares
CY2022	oprx	Shares Of Common Stock Options SharesOfCommonStockOptions	410701	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	128590
CY2021Q4	us-gaap	Deferred Compensation Arrangement With Individual Shares Authorized For Issuance DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance	2500000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	896169	shares
CY2022	oprx	Common Stock Restricted Stock Unit CommonStockRestrictedStockUnit	660484	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	921946	shares
CY2022	oprx	Fair Market Value Rate FairMarketValueRate	1	pure
CY2021	oprx	Options Exercised Value OptionsExercisedValue	100290	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1545518	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.31
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	424588	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	54.34
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1105822	shares
CY2021	oprx	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	7.33
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	783547	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.17
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23368961	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	862938	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.43
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	156910	shares
CY2022	oprx	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	7.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	182705	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	37.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1306870	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.14
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1537752	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	250684	shares
CY2022	oprx	Share Based Compensation Arrangements By Share Based Payment Award Options Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice	33.82
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M6D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	538652	usd
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	586276	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	42.01
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	862938	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.43
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	223323	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	35.04
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	169705	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	37.83
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1056186	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	30.51
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	12528706	usd
CY2022	oprx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2022	oprx	Share Based Compensations Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationsArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	P12M
CY2020Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	100000	shares
CY2021	oprx	Grant Date Fair Value Outstanding Beginning GrantDateFairValueOutstandingBeginning	11.51
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	303556	shares
CY2021	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueGranted	66.3
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	485	shares
CY2021	oprx	Grant Date Fair Value Forfeited GrantDateFairValueForfeited	61.82
CY2021	oprx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Shares Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsSharesIssued	-3333	shares
CY2021	oprx	Weightedgrantdatefairvalue Sharesissued WeightedgrantdatefairvalueSharesissued	21.2
CY2021Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	399738	shares
CY2021	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding Ending SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueOutstandingEnding	52.99
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	467043	shares
CY2022	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Granted SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueGranted	25.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	39346	shares
CY2022	oprx	Grant Date Fair Value Forfeited GrantDateFairValueForfeited	44.06
CY2022	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Vested And Issued SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesVestedAndIssued	-29945	shares
CY2022	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Vested And Issued SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueVestedAndIssued	59.41
CY2022	oprx	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrumentswithheldandcancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentswithheldandcancelled	-8416	shares
CY2022	oprx	Weightedgrantdatefairvalue Withheldandcancelled WeightedgrantdatefairvalueWithheldandcancelled	68.69
CY2022Q4	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Shares Outstanding Beginning SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsSharesOutstandingBeginning	789074	shares
CY2022	oprx	Sharebased Compensation Arrangement By Sharebased Payment Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding Ending SharebasedCompensationArrangementBySharebasedPaymentRestrictedStockAwardsWeightedAverageGrantDateFairValueOutstandingEnding	36.95
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P2Y
CY2022	oprx	Granted Restricted Stock Description GrantedRestrictedStockDescription	The Company granted restricted stock units of 467,043 and 303,556 units in 2022 and 2021, respectively, and valued at $11,996,111 and $20,125,861, respectively. These restricted stock units vest over a period of 1 year to 5 years. The Company recognized expense of $10,789,203 and $2,532,091 in 2022 and 2021, respectively, related to these restricted stock units.
CY2022	oprx	Restricted Stock Granted Remains Value RestrictedStockGrantedRemainsValue	17862951	usd
CY2022	oprx	Remains To Be Recognized Over A Period RemainsToBeRecognizedOverAPeriod	P2Y
CY2022	oprx	Cumulative Net Shares Issued Surrendered CumulativeNetSharesIssuedSurrendered	31243	shares
CY2022	oprx	Cumulative Net Shares Issued Cancelled CumulativeNetSharesIssuedCancelled	100290	shares
CY2021	oprx	Restricted Stock Units Description RestrictedStockUnitsDescription	Of the restricted stock units issued in 2021, 182,938 are market-based awards that vest if the Company’s stock price hits certain price targets and maintains that price for 30 days. A total of 60,191, 60,191, and 62,016 units vest if the stock price hits $98.87, $131.82, and $164.78, respectively. As described in Note 2, these market-based restricted stock units were valued using a Monte Carlo simulation model, with expected vesting in 1.60, 2.25, and 2.71 years, respectively, for the three price targets. During the year ended December 31, 2022, we granted certain performance based stock units, the expense for which will be recorded over time once the achievement of the performance is deemed probable.
CY2022Q4	us-gaap	Shares Issued SharesIssued	4730	shares
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	250085	usd
CY2022	oprx	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3715	shares
CY2022	oprx	Stock Issued During Period Shares Restricted Stocks Award Gross StockIssuedDuringPeriodSharesRestrictedStocksAwardGross	26470	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	750130	usd
CY2022	oprx	Operating Leases Expires Period OperatingLeasesExpiresPeriod	2023-11-30
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	We have assumed renewal of the lease. We also had a lease on office space in Cranbury, New Jersey, which expired in January 2022 with a monthly payment of $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2024.
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	100771	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	132305	usd
CY2022	us-gaap	Lease Cost LeaseCost	176555	usd
CY2021	us-gaap	Lease Cost LeaseCost	184680	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	98247	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	80215	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	70224	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	248686	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14252	usd
CY2022	oprx	Total Lease Liabilities TotalLeaseLiabilities	234434	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2022	oprx	Measurement Of Lease Liabilities MeasurementOfLeaseLiabilities	89111	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	101405	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	101433	usd
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	142284	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	121129	usd
CY2022	oprx	Concentration Risk Percentage ConcentrationRiskPercentage	0.10	pure
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	789000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	126000	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	As of December 31, 2022, the Company had net operating loss (“NOLs”) carry-forwards for federal income tax purposes of approximately $21.5 million, consisting of pre-2018 losses in the amount of approximately $8.2 million that expire from 2022 through 2037, and post-2017 losses in the amount of approximately $13.3 million that will never expire.
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2402000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-79000	usd
CY2022	oprx	Federal Income Tax State Tax Effect Net Of Federal Benefit FederalIncomeTaxStateTaxEffectNetOfFederalBenefit	545000	usd
CY2021	oprx	Federal Income Tax State Tax Effect Net Of Federal Benefit FederalIncomeTaxStateTaxEffectNetOfFederalBenefit	979000	usd
CY2022	oprx	Federal Income Tax Option Exercise Benefits Net Of Section162 M Limitations FederalIncomeTaxOptionExerciseBenefitsNetOfSection162MLimitations	-268000	usd
CY2021	oprx	Federal Income Tax Option Exercise Benefits Net Of Section162 M Limitations FederalIncomeTaxOptionExerciseBenefitsNetOfSection162MLimitations	2171000	usd
CY2022	oprx	Federal Income Tax Other Adjustments FederalIncomeTaxOtherAdjustments	221000	usd
CY2021	oprx	Federal Income Tax Other Adjustments FederalIncomeTaxOtherAdjustments	-30000	usd
CY2021Q4	oprx	Federal Income Tax Net Operating Loss Expiring FederalIncomeTaxNetOperatingLossExpiring	-26000	usd
CY2022	oprx	Federal Income Tax Expenses Benefit Value Allowance FederalIncomeTaxExpensesBenefitValueAllowance	-2900000	usd
CY2021	oprx	Federal Income Tax Expenses Benefit Value Allowance FederalIncomeTaxExpensesBenefitValueAllowance	-3006000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5545000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6887000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3953000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	809000	usd
CY2022Q4	oprx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	63000	usd
CY2021Q4	oprx	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	88000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	13000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	85000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7882000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2102000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2490000	usd
CY2022Q4	oprx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-63000	usd
CY2021Q4	oprx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	-88000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-106000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-59000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-42000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2330000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2620000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8162000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5262000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8162000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5262000	usd
CY2022	oprx	Underpayment Percentage UnderpaymentPercentage	0.10	pure
CY2022	oprx	Future Minimum Payments FutureMinimumPayments	16400000	usd
CY2022	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll.
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	489780	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	343221	usd
CY2022	dei	City Area Code CityAreaCode	248
CY2022	dei	Local Phone Number LocalPhoneNumber	651-6568
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid		usd
CY2021	oprx	Shares Issued In Connection With Acquisitions SharesIssuedInConnectionWithAcquisitions		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2022	oprx	Effect Of Dilutive Securities Shares EffectOfDilutiveSecuritiesShares		shares
CY2022	oprx	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount
CY2021	oprx	Effect Of Dilutive Securities Per Share Amount EffectOfDilutiveSecuritiesPerShareAmount
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022Q4	us-gaap	Goodwill Not Allocated Amount GoodwillNotAllocatedAmount		usd
CY2022Q4	oprx	Federal Income Tax Net Operating Loss Expiring FederalIncomeTaxNetOperatingLossExpiring		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions		usd
CY2021	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts		usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10492000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2022	oprx	Deferred Tax Asset Net Of Valuation Allowance DeferredTaxAssetNetOfValuationAllowance		usd
CY2021	oprx	Deferred Tax Asset Net Of Valuation Allowance DeferredTaxAssetNetOfValuationAllowance		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-23-019233-index-headers.html	Edgar Link	pending
0001213900-23-019233-index.html	Edgar Link	pending
0001213900-23-019233.txt	Edgar Link	pending
0001213900-23-019233-xbrl.zip	Edgar Link	pending
ex10-19_001.jpg	Edgar Link	pending
f10k2022ex10-18_optimizerx.htm	Edgar Link	pending
f10k2022ex10-19_optimizerx.htm	Edgar Link	pending
f10k2022ex21-1_optimizerx.htm	Edgar Link	pending
f10k2022ex23-1_optimizerx.htm	Edgar Link	pending
f10k2022ex3-3_optimizerx.htm	Edgar Link	pending
f10k2022ex31-1_optimizerx.htm	Edgar Link	pending
f10k2022ex31-2_optimizerx.htm	Edgar Link	pending
f10k2022ex32-1_optimizerx.htm	Edgar Link	pending
f10k2022_optimizerx.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
oprx-20221231_cal.xml	Edgar Link	unprocessable
oprx-20221231_def.xml	Edgar Link	unprocessable
oprx-20221231_pre.xml	Edgar Link	unprocessable
f10k2022_optimizerx_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
oprx-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2023 Q1 Form 10-K Financial Statement

#000121390023019233 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2023 Q1 Form 10-K Financial Statement

#000121390023019233 Filed on March 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx